These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 20060157)

  • 21. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
    Maguire B; Whitaker D; Carrello S; Spagnolo D
    Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
    Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
    Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
    Dejmek A
    Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EZH2, a unique marker of malignancy in effusion cytology.
    Jiang H; Gupta R; Somma J
    Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A panel of markers for identification of malignant and non-malignant cells in culture from effusions.
    Carneiro FP; Muniz-Junqueira MI; Pittella-Silva F; Carneiro MV; Takano GHS; Vianna LMS; De Andrade LB; De Castro TMML; Peres I; Dos Santos Borges TK; Ferreira VM; Motoyama AB
    Oncol Rep; 2017 Dec; 38(6):3538-3544. PubMed ID: 29039588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
    Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
    Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
    Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
    Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
    Chen CJ; Chang SC; Tseng HH
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.
    Mocanu L; Cîmpean AM; Raica M
    Rom J Morphol Embryol; 2006; 47(4):351-5. PubMed ID: 17392981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
    Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
    Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
    Ferrandez-Izquierdo A; Navarro-Fos S; Gonzalez-Devesa M; Gil-Benso R; Llombart-Bosch A
    Diagn Cytopathol; 1994; 10(3):256-62. PubMed ID: 7519540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
    Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
    Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
    Cakir E; Demirag F; Aydin M; Unsal E
    Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
    Kitazume H; Kitamura K; Mukai K; Inayama Y; Kawano N; Nakamura N; Sano J; Mitsui K; Yoshida S; Nakatani Y
    Cancer; 2000 Feb; 90(1):55-60. PubMed ID: 10692217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.